Candida glabrata persistence in mice does not depend on host immunosuppression and is unaffected by fungal amino acid auxotrophy

Infection and Immunity

Volumn 78, Issue 3, 2010, Pages 1066-1077

  Jacobsen, I D ^a   Brunke, S ^a   Seider, K ^a   Schwarzmuller T ^c   Firon, A ^d,e   D'Enfert C ^d,e   Kuchler, K ^c   Hube, B ^a,b  

^a HANS KNÖLL INSTITUTE   (Germany)

^b FRIEDRICH SCHILLER UNIVERSITY JENA   (Germany)

^c MEDICAL UNIVERSITY OF VIENNA   (Austria)

^d INSTITUT PASTEUR   (France)

^e INRA USC 2019   (France)

Author keywords

[No Author keywords available]

Indexed keywords

CORTICOSTEROID; CYTOKINE; HISTIDINE; LEUCINE; MYELOPEROXIDASE; TRYPTOPHAN;

ANIMAL TISSUE; ARTICLE; AUXOTROPHY; CANDIDA GLABRATA; CONTROLLED STUDY; ENZYME BLOOD LEVEL; FEMALE; FUNGAL STRAIN; FUNGAL VIRULENCE; HISTOLOGY; IMMUNE RESPONSE; IMMUNOCOMPETENCE; IMMUNOSUPPRESSIVE TREATMENT; LEUKOPENIA; MOUSE; MYCOSIS; NONHUMAN; PRIORITY JOURNAL; TISSUE INJURY;

ALANINE TRANSAMINASE; AMINO ACIDS; ANIMAL STRUCTURES; ANIMALS; ASPARTATE AMINOTRANSFERASES; CANDIDA GLABRATA; CANDIDIASIS; COLONY COUNT, MICROBIAL; DISEASE MODELS, ANIMAL; FEMALE; IMMUNOSUPPRESSION; MICE;

EID: 77349112887     PISSN: 00199567     EISSN: 10985522     Source Type: Journal    
DOI: 10.1128/IAI.01244-09     Document Type: Article

References (47)

1. Arendrup, M., T. Horn, and N. Frimodt-Moller. 2002. In vivo pathogenicity of eight medically relevant Candida species in an animal model. Infection 30:286-291.
2. Atkinson, B. A., C. Bouthet, R. Bocanegra, A. Correa, M. F. Luther, and J. R. Graybill. 1995. Comparison of fluconazole, amphotericin B and flucytosine in treatment of a murine model of disseminated infection with Candida glabrata in immunocompromised mice. J. Antimicrob. Chemother. 35:631-640.
3. Bain, J. M., C. Stubberfield, and N. A. Gow. 2001. Ura-status-dependent adhesion of Candida albicans mutants. FEMS Microbiol. Lett. 204:323-328.
4. Barchiesi, F., E. Spreghini, S. Tomassetti, D. Arzeni, D. Giannini, and G. Scalise. 2005. Comparison of the fungicidal activities of caspofungin and amphotericin B against Candida glabrata. Antimicrob. Agents Chemother. 49:4989-4992.
5. 2+-ATPase, is required for glycosylation and virulence. J. Biol. Chem. 280:23408-23415.
6. Brieland, J., D. Essig, C. Jackson, D. Frank, D. Loebenberg, F. Menzel, B. Arnold, B. DiDomenico, and R. Hare. 2001. Comparison of pathogenesis and host immune responses to Candida glabrata and Candida albicans in systemically infected immunocompetent mice. Infect. Immun. 69:5046-5055.
7. Brummer, E., A. Maqbool, and D. A. Stevens. 2002. Protection of peritoneal macrophages by granulocyte/macrophage colony-stimulating factor (GMCSF) against dexamethasone suppression of killing of Aspergillus, and the effect of human GM-CSF. Microbes Infect. 4:133-138.
8. Chen, G. H., M. A. Olszewski, R. A. McDonald, J. C. Wells, R. Paine III, G. B. Huffnagle, and G. B. Toews. 2007. Role of granulocyte macrophage colony-stimulating factor in host defense against pulmonary Cryptococcus neoformans infection during murine allergic bronchopulmonary mycosis. Am. J. Pathol. 170:1028-1040.
9. D'Enfert, C., M. Diaquin, A. Delit, N. Wuscher, J. P. Debeaupuis, M. Huerre, and J. P. Latge. 1996. Attenuated virulence of uridine-uracil auxotrophs of Aspergillus fumigatus. Infect. Immun. 64:4401-4405.
10. Fidel, P. L., Jr., J. A. Vazquez, and J. D. Sobel. 1999. Candida glabrata: review of epidemiology, pathogenesis, and clinical disease with comparison to C. albicans. Clin. Microbiol. Rev. 12:80-96.
11. Goldstein, A. L., and J. H. McCusker. 2001. Development of Saccharomyces cerevisiae as a model pathogen. A system for the genetic identification of gene products required for survival in the mammalian host environment. Genetics 159:499-513.
12. Hachem, R., H. Hanna, D. Kontoyiannis, Y. Jiang, and I. Raad. 2008. The changing epidemiology of invasive candidiasis: Candida glabrata and Candida krusei as the leading causes of candidemia in hematologic malignancy. Cancer 112:2493-2499.
13. Ito, J. I., and J. M. Lyons. 2002. Vaccination of corticosteroid immunosuppressed mice against invasive pulmonary aspergillosis. J. Infect. Dis. 186: 869-871.
14. phox mouse knock-out model of chronic granulomatous disease. J. Exp. Med. 182:751-758.
15. phox-/- knockout mice. Antimicrob. Agents Chemother. 46:1240-1245.
16. Kaur, R., B. Ma, and B. P. Cormack. 2007. A family of glycosylphosphatidylinositol-linked aspartyl proteases is required for virulence of Candida glabrata. Proc. Natl. Acad. Sci. U. S. A. 104:7628-7633.
17. Kirsch, D. R., and R. R. Whitney. 1991. Pathogenicity of Candida albicans auxotrophic mutants in experimental infections. Infect. Immun. 59:3297-3300.
18. Klebanoff, S. J. 2005. Myeloperoxidase: friend and foe. J. Leukoc. Biol. 77:598-625.
19. Krawisz, J. E., P. Sharon, and W. F. Stenson. 1984. Quantitative assay for acute intestinal inflammation based on myeloperoxidase activity. Assessment of inflammation in rat and hamster models. Gastroenterology 87:1344-1350.
20. Kretschmar, M., B. Hube, T. Bertsch, D. Sanglard, R. Merker, M. Schroder, H. Hof, and T. Nichterlein. 1999. Germ tubes and proteinase activity contribute to virulence of Candida albicans in murine peritonitis. Infect. Immun. 67:6637-6642.
21. Li, L., and A. Dongari-Bagtzoglou. 2009. Epithelial GM-CSF induction by Candida glabrata. J. Dent. Res. 88:746-751.
22. Li, L., H. Kashleva, and A. Dongari-Bagtzoglou. 2007. Cytotoxic and cytokine-inducing properties of Candida glabrata in single and mixed oral infection models. Microb. Pathog. 42:138-147.
23. Lin, Y., J. Cai, J. D. Turner, and X. Zhao. 1996. Quantification of bovine neutrophil migration across mammary epithelium in vitro. Can. J. Vet. Res. 60:145-149.
24. MacCallum, D. M. 2009. Massive induction of innate immune response to Candida albicans in the kidney in a murine intravenous challenge model. FEMS Yeast Res. 9:1111-1122.
25. MacCallum, D. M., L. Castillo, A. J. Brown, N. A. Gow, and F. C. Odds. 2009. Early-expressed chemokines predict kidney immunopathology in experimental disseminated Candida albicans infections. PLoS One 4:e6420.
26. Malani, A., J. Hmoud, L. Chiu, P. L. Carver, A. Bielaczyc, and C. A. Kauffman. 2005. Candida glabrata fungemia: experience in a tertiary care center. Clin. Infect. Dis. 41:975-981.
27. Manning, M., C. B. Snoddy, and R. A. Fromtling. 1984. Comparative pathogenicity of auxotrophic mutants of Candida albicans. Can. J. Microbiol. 30:31-35.
28. Mariné, M., R. Espada, J. Torrado, F. J. Pastor, and J. Guarro. 2008. Efficacy of a new formulation of amphotericin B in a murine model of disseminated infection by Candida glabrata. J. Antimicrob. Chemother. 61: 880-883.
29. Marriott, D. J., E. G. Playford, S. Chen, M. Slavin, Q. Nguyen, D. Ellis, and T. C. Sorrell. 2009. Determinants of mortality in non-neutropenic ICU patients with candidaemia. Crit. Care 13:R115.
30. Naito, M., S. Umeda, T. Yamamoto, H. Moriyama, H. Umezu, G. Hasegawa, H. Usuda, L. D. Shultz, and K. Takahashi. 1996. Development, differentiation, and phenotypic heterogeneity of murine tissue macrophages. J. Leukoc. Biol. 59:133-138.
31. Noble, S. M., and A. D. Johnson. 2005. Strains and strategies for large-scale gene deletion studies of the diploid human fungal pathogen Candida albicans. Eukaryot. Cell 4:298-309.
32. Odds, F. C. 1988. Candida and candidosis, 2nd ed., p. 68-93. Baillière Tindall, London, United Kingdom.
33. Perlroth, J., B. Choi, and B. Spellberg. 2007. Nosocomial fungal infections: epidemiology, diagnosis, and treatment. Med. Mycol. 45:321-346.
34. Pfaller, M. A., and D. J. Diekema. 2007. Epidemiology of invasive candidiasis: a persistent public health problem. Clin. Microbiol. Rev. 20:133-163.
35. Playford, E. G., D. Marriott, Q. Nguyen, S. Chen, D. Ellis, M. Slavin, and T. C. Sorrell. 2008. Candidemia in nonneutropenic critically ill patients: risk factors for non-albicans Candida spp. Crit. Care Med. 36:2034-2039.
36. Quezada, G., N. V. Koshkina, P. Zweidler-McKay, Z. Zhou, D. P. Kontoyiannis, and E. S. Kleinerman. 2008. Intranasal granulocyte-macrophage colony-stimulating factor reduces the Aspergillus burden in an immunosuppressed murine model of pulmonary aspergillosis. Antimicrob. Agents Chemother. 52:716-718.
37. Reuss, O., A. Vik, R. Kolter, and J. Morschhauser. 2004. The SAT1 flipper, an optimized tool for gene disruption in Candida albicans. Gene 341:119-127.
38. Safdar, A., T. W. Bannister, and Z. Safdar. 2004. The predictors of outcome in immunocompetent patients with hematogenous candidiasis. Int. J. Infect. Dis. 8:180-186.
39. Schaller, M., R. Mailhammer, G. Grassl, C. A. Sander, B. Hube, and H. C. Korting. 2002. Infection of human oral epithelia with Candida species induces cytokine expression correlated to the degree of virulence. J. Invest. Dermatol. 118:652-657.
40. Sipsas, N. V., R. E. Lewis, J. Tarrand, R. Hachem, K. V. Rolston, I. I. Raad, and D. P. Kontoyiannis. 2009. Candidemia in patients with hematologic malignancies in the era of new antifungal agents (2001-2007): stable incidence but changing epidemiology of a still frequently lethal infection. Cancer 115:4745-4752.
41. Smith, P. J., J. A. Olson, D. Constable, J. Schwartz, R. T. Proffitt, and J. P. Adler-Moore. 2007. Effects of dosing regimen on accumulation, retention and prophylactic efficacy of liposomal amphotericin B. J. Antimicrob. Chemother. 59:941-951.
42. Spellberg, B., A. S. Ibrahim, J. E. Edwards, Jr., and S. G. Filler. 2005. Mice with disseminated candidiasis die of progressive sepsis. J. Infect. Dis. 192: 336-343.
43. Srikantha, T., K. J. Daniels, W. Wu, S. R. Lockhart, S. Yi, N. Sahni, N. Ma, and D. R. Soll. 2008. Dark brown is the more virulent of the switch phenotypes of Candida glabrata. Microbiology 154:3309-3318.
44. Staab, J. F., and P. Sundstrom. 2003. URA3 as a selectable marker for disruption and virulence assessment of Candida albicans genes. Trends Microbiol. 11:69-73.
45. St Onge, R. P., R. Mani, J. Oh, M. Proctor, E. Fung, R. W. Davis, C. Nislow, F. P. Roth, and G. Giaever. 2007. Systematic pathway analysis using high-resolution fitness profiling of combinatorial gene deletions. Nat. Genet. 39:199-206.
46. Tsoni, S. V., A. M. Kerrigan, M. J. Marakalala, N. Srinivasan, M. Duffield, P. R. Taylor, M. Botto, C. Steele, and G. D. Brown. 2009. Complement C3 plays an essential role in the control of opportunistic fungal infections. Infect. Immun. 77:3679-3685.
47. Warn, P. A., M. W. Brampton, A. Sharp, G. Morrissey, N. Steel, D. W. Denning, and T. Priest. 2003. Infrared body temperature measurement of mice as an early predictor of death in experimental fungal infections. Lab. Anim. 37:126-131.